U.S. markets closed
  • S&P 500

    3,790.93
    +112.50 (+3.06%)
     
  • Dow 30

    30,316.32
    +825.43 (+2.80%)
     
  • Nasdaq

    11,176.41
    +360.97 (+3.34%)
     
  • Russell 2000

    1,775.77
    +66.90 (+3.91%)
     
  • Crude Oil

    86.37
    -0.15 (-0.17%)
     
  • Gold

    1,734.00
    +3.50 (+0.20%)
     
  • Silver

    21.10
    +0.01 (+0.03%)
     
  • EUR/USD

    0.9985
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    3.6170
    -0.0340 (-0.93%)
     
  • GBP/USD

    1.1461
    -0.0014 (-0.12%)
     
  • USD/JPY

    144.0580
    -0.1410 (-0.10%)
     
  • BTC-USD

    20,297.10
    +672.91 (+3.43%)
     
  • CMC Crypto 200

    460.91
    +15.47 (+3.47%)
     
  • FTSE 100

    7,086.46
    +177.70 (+2.57%)
     
  • Nikkei 225

    26,992.21
    +776.42 (+2.96%)
     

Abbott (ABT) Gains But Lags Market: What You Should Know

·3 min read

In the latest trading session, Abbott (ABT) closed at $104.09, marking a +0.09% move from the previous day. The stock lagged the S&P 500's daily gain of 0.69%. Meanwhile, the Dow gained 0.64%, and the Nasdaq, a tech-heavy index, lost 0.2%.

Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had lost 5.51% over the past month. This has was narrower than the Medical sector's loss of 5.7% and the S&P 500's loss of 9.94% in that time.

Abbott will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0.89, down 36.43% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $9.57 billion, down 12.46% from the year-ago period.

Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $4.99 per share and revenue of $42.39 billion. These totals would mark changes of -4.22% and -1.59%, respectively, from last year.

It is also important to note the recent changes to analyst estimates for Abbott. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Abbott is holding a Zacks Rank of #3 (Hold) right now.

Looking at its valuation, Abbott is holding a Forward P/E ratio of 20.85. For comparison, its industry has an average Forward P/E of 20.85, which means Abbott is trading at a no noticeable deviation to the group.

Investors should also note that ABT has a PEG ratio of 3.85 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Products stocks are, on average, holding a PEG ratio of 2.11 based on yesterday's closing prices.

The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 174, putting it in the bottom 31% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Abbott Laboratories (ABT) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research